Hls Therapeutics Stock Net Income
| HLS Stock | CAD 4.65 0.05 1.06% |
As of the 29th of January, HLS Therapeutics retains the risk adjusted performance of (0.12), and Market Risk Adjusted Performance of 0.3727. HLS Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
HLS Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.6911 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -17.7 M | -16.8 M | |
| Net Loss | -17.7 M | -18.6 M | |
| Net Loss | -17.7 M | -18.6 M | |
| Net Loss | (0.71) | (0.67) | |
| Net Income Per E B T | 1.45 | 1.36 |
HLS | Net Income |
Latest HLS Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of HLS Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in HLS Therapeutics financial statement analysis. It represents the amount of money remaining after all of HLS Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is HLS Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (19.66 M) | 10 Years Trend |
|
Net Income |
| Timeline |
HLS Net Income Regression Statistics
| Arithmetic Mean | (7,564,014) | |
| Geometric Mean | 11,101,239 | |
| Coefficient Of Variation | (195.58) | |
| Mean Deviation | 12,942,165 | |
| Median | (13,117,000) | |
| Standard Deviation | 14,793,678 | |
| Sample Variance | 218.9T | |
| Range | 44.4M | |
| R-Value | (0.86) | |
| Mean Square Error | 61.9T | |
| R-Squared | 0.73 | |
| Significance | 0.000011 | |
| Slope | (2,511,237) | |
| Total Sum of Squares | 3501.6T |
HLS Net Income History
HLS Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for HLS Therapeutics is extremely important. It helps to project a fair market value of HLS Stock properly, considering its historical fundamentals such as Net Income. Since HLS Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HLS Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HLS Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
HLS Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to HLS Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of HLS Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in HLS Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding HLS Therapeutics or generate 0.0% return on investment in HLS Therapeutics over 90 days. HLS Therapeutics is related to or competes with Cannara Biotech, Cardiol Therapeutics, Auxly Cannabis, Helix BioPharma, Biosyent, and Quipt Home. HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical produ... More
HLS Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure HLS Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess HLS Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 10.37 | |||
| Value At Risk | (2.04) | |||
| Potential Upside | 1.97 |
HLS Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for HLS Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as HLS Therapeutics' standard deviation. In reality, there are many statistical measures that can use HLS Therapeutics historical prices to predict the future HLS Therapeutics' volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | 0.3627 |
HLS Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | 0.3727 | |||
| Mean Deviation | 1.08 | |||
| Coefficient Of Variation | (584.30) | |||
| Standard Deviation | 1.57 | |||
| Variance | 2.47 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | 0.3627 | |||
| Maximum Drawdown | 10.37 | |||
| Value At Risk | (2.04) | |||
| Potential Upside | 1.97 | |||
| Skewness | (1.03) | |||
| Kurtosis | 6.97 |
HLS Therapeutics Backtested Returns
HLS Therapeutics holds Efficiency (Sharpe) Ratio of -0.18, which attests that the entity had a -0.18 % return per unit of volatility over the last 3 months. HLS Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out HLS Therapeutics' risk adjusted performance of (0.12), and Market Risk Adjusted Performance of 0.3727 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of -0.77, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning HLS Therapeutics are expected to decrease at a much lower rate. During the bear market, HLS Therapeutics is likely to outperform the market. At this point, HLS Therapeutics has a negative expected return of -0.29%. Please make sure to check out HLS Therapeutics' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if HLS Therapeutics performance from the past will be repeated at future time.
Auto-correlation | 0.55 |
Modest predictability
HLS Therapeutics has modest predictability. Overlapping area represents the amount of predictability between HLS Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of HLS Therapeutics price movement. The serial correlation of 0.55 indicates that about 55.0% of current HLS Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.55 | |
| Spearman Rank Test | 0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
HLS Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, HLS Therapeutics reported net income of (19.66 Million). This is 105.76% lower than that of the Pharmaceuticals sector and 94.9% lower than that of the Health Care industry. The net income for all Canada stocks is 103.44% higher than that of the company.
HLS Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HLS Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HLS Therapeutics could also be used in its relative valuation, which is a method of valuing HLS Therapeutics by comparing valuation metrics of similar companies.HLS Therapeutics is currently under evaluation in net income category among its peers.
HLS Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of HLS Therapeutics from analyzing HLS Therapeutics' financial statements. These drivers represent accounts that assess HLS Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of HLS Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 371.4M | 235.1M | 123.9M | 85.6M | 77.1M | 69.4M | |
| Enterprise Value | 447.8M | 311.8M | 189.6M | 134.6M | 121.2M | 89.9M |
HLS Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0186 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 204.3 M | ||||
| Shares Outstanding | 31.27 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 43.26 % | ||||
| Number Of Shares Shorted | 2.12 K | ||||
| Price To Book | 1.73 X | ||||
| Price To Sales | 2.61 X | ||||
| Revenue | 56.62 M | ||||
| Gross Profit | 40.11 M | ||||
| EBITDA | 17.22 M | ||||
| Net Income | (19.66 M) | ||||
| Cash And Equivalents | 20.72 M | ||||
| Cash Per Share | 1.70 X | ||||
| Total Debt | 66.45 M | ||||
| Debt To Equity | 50.50 % | ||||
| Current Ratio | 1.70 X | ||||
| Book Value Per Share | 2.68 X | ||||
| Cash Flow From Operations | 8 M | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | (0.61) X | ||||
| Target Price | 7.66 | ||||
| Number Of Employees | 92 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 145.98 M | ||||
| Total Asset | 159.9 M | ||||
| Retained Earnings | (194.18 M) | ||||
| Working Capital | 12.86 M | ||||
| Net Asset | 159.9 M | ||||
| Last Dividend Paid | 0.076 |
About HLS Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HLS Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HLS Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HLS Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.